J Retin.  2021 Nov;6(2):150-154. 10.21561/jor.2021.6.2.150.

Effect of High-dose Intravitreal Bevacizumab Injection on Refractory Idiopathic Choroidal Neovasculariz

• Bang JW

• KMID: 2552183
• DOI: http://doi.org/10.21561/jor.2021.6.2.150

Abstract

Purpose
To report the effect of high-dose intravitreal bevacizumab injection on refractory idiopathic choroidal neovascularization.
Case summary
A 43-year-old male presented with vision loss in his right eye 7 days earlier. His best corrected visual acuity was counting fingers at 30 cm. In optical coherence tomography, macular edema, submacular hemorrhage, and subretinal fluid were observed; in FA, foveal leakage was observed. After three intravitreal ranibizumab injections and two intravitreal aflibercept injections, his best corrected visual acuity was 20/800, and macular edema and subretinal fluid persisted. After switching to high-dose intravitreal bevacizumab injection, gradual improvement of best corrected visual acuity and macular structural recovery were observed. After 5 monthly high-dose intravitreal bevacizumab injections, his best corrected visual acuity was 20/125, and macular edema was decreased.
Conclusions
We can consider high-dose intravitreal bevacizumab injection in a refractory idiopathic choroidal neovascularization patient as a treatment option.

Keyword

Bevacizumab; Choroidal neovascularization; Macular edema; Ranibizumab; Subretinal fluid